Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664950 | 0.81 | CA1 (0.46) | CA1CA2GAAPOLBKMT2A | |
| SCHEMBL1705467 | 0.76 | GAA (0.46) | CA1CA2GAAPOLBKMT2A | |
| SCHEMBL3204515 | 0.74 | GAA (0.49) | CA1CA2GAAPOLBKMT2A | |
| SCHEMBL13249203 | 0.72 | GAA (0.47) | CA1CA2GAAPOLBKMT2A | |
| SCHEMBL19631003 | 0.72 | GAA (0.47) | CA1CA2GAAPOLBKMT2A | |
| SCHEMBL3209417 | 0.71 | GAA (0.46) | CA1CA2GAAPOLBKMT2A | |
| SCHEMBL27994172 | 0.70 | CA1 (0.55) | CA1CA2GAAPOLBKMT2A | |
| SCHEMBL19630970 | 0.70 | GAA (0.45) | CA1CA2GAAPOLBKMT2A | |
| SCHEMBL25240442 | 0.69 | GAA (0.45) | CA1CA2GAAPOLBKMT2A | |
| SCHEMBL19630955 | 0.69 | GAA (0.53) | CA1CA2GAAPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586612-B2 | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-8586612-B2 | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| CN-101080388-B | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI AVENTIS DEUTSCHLAND | 2010-12-22 | — | — | CN | disclosed |
| CN-101080388-B | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI AVENTIS DEUTSCHLAND | 2010-12-22 | — | — | CN | disclosed |
| EP-1828131-B1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-06-04 | — | — | EP | disclosed |
| EP-1828131-B1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-06-04 | — | — | EP | disclosed |
| US-20080033016-A1 | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-07 | — | — | US | disclosed |
| US-20080033016-A1 | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-07 | — | — | US | disclosed |
| CN-101080388-A | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-11-28 | — | — | CN | disclosed |
| CN-101080388-A | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-11-28 | — | — | CN | disclosed |
| EP-1828131-A1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Sanofi-Aventis Deutschland GmbH (DE) | 2007-09-05 | — | — | EP | disclosed |
| EP-1828131-A1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Sanofi-Aventis Deutschland GmbH (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063722-A1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006063722-A1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-06-22 | — | — | WO | disclosed |
| US-4315940-A | Antidiabetic 1-piperidine-sulfonylureas | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033016-A1 | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | ATP2A1, ATP2A3, ATP2A2 | CA1 3827/4885CA2 844/4885GAA 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.